International symposium on substance P and related peptides : pain, inflammation, visceral and CNS functionsRegulatory peptides. 1993, Vol 46, Num 1-2, issn 0167-0115, 502 p.Conference Proceedings

Reward for persistence in substance P researchWAHLESTEDT, C.Science (Washington, D.C.). 1998, Vol 281, Num 5383, pp 1624-1625, issn 0036-8075Article

Neural contractions in colonic strips from patients with diverticular disease : role of endocannabinoids and substance PGUAGNINI, F; VALENTI, M; MUKENGE, S et al.Gut. 2006, Vol 55, Num 7, pp 946-953, issn 0017-5749, 8 p.Article

α-Bungarotoxin interacts with the rat brain tachykinin receptorsUTKIN, YU. N; LAZAKOVICH, E. M; KASHEVEROV, I. E et al.FEBS letters. 1989, Vol 255, Num 1, pp 111-115, issn 0014-5793, 5 p.Article

Role of substance P in hypersensitivity reactions induced by paclitaxel, an anticancer agentSENDO, Toshiaki; ITOH, Yoshinori; GOROMARU, Takeshi et al.Peptides (New York, NY. 1980). 2004, Vol 25, Num 7, pp 1205-1208, issn 0196-9781, 4 p.Article

Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptidesBATHON, J. M; PROUD, D; MIZUTANI, S et al.The Journal of clinical investigation. 1992, Vol 90, Num 3, pp 981-991, issn 0021-9738Article

The significance of substance P in physiological and malignant haematopoiesisNOWICKI, Michal; OSTALSKA-NOWICKA, Danuta; KONDRACIUK, Beata et al.Journal of clinical pathology. 2007, Vol 60, Num 7, pp 749-755, issn 0021-9746, 7 p.Article

Cyclosporin A is a substance P (tachykinin NK₁) receptor antagonistGITTER, B. D; WATERS, D. C; THRELKELD, P. G et al.European journal of pharmacology. Molecular pharmacology section. 1995, Vol 289, Num 3, pp 439-446, issn 0922-4106Article

Sustancia P en dermatología = Substance P in dermatologyGOMEZ-MELGAR, M. R; SAUL, A.Dermatología. 1993, Vol 37, Num 3, pp 169-173, issn 0185-4038Article

Evaluation du temps de rétention de peptides en électrophorèse capillaire = Evaluation of peptides retention time with capillary electrophoresisZHU, M; HANSEN, D; BURD, S et al.Spectra 2000. 1989, Vol 17, Num 143, pp 27-28, issn 0399-1172Article

Substance P as a transmitter in the human ciliary muscleLOGRANO, M. D; DANIELE, E.Pharmacological research communications. 1988, Vol 20, Num 10, pp 901-905, issn 0031-6989Article

A phorbol ester inhibits the release of endothelium-derived relaxing factorLEWIS, M. J; HENDERSON, A. H.European journal of pharmacology. 1987, Vol 137, Num 2-3, pp 167-171, issn 0014-2999Article

Characterization of a conformationally sensitive TOAC spin-labeled substance PSHAFER, Aaron M; NAKAIE, Clovis R; DEUPI, Xavier et al.Peptides (New York, NY. 1980). 2008, Vol 29, Num 11, pp 1919-1929, issn 0196-9781, 11 p.Article

The role of substance P in the pathogenesis of pterygiaCHUI, Jeanie; DI GIROLAMO, Nick; CORONEO, Minas T et al.Investigative ophthalmology & visual science. 2007, Vol 48, Num 10, pp 4482-4489, issn 0146-0404, 8 p.Article

Solution conformation of substance P antagonists-[D-Arg¹, D-Trp^7,9, Leu¹¹]-SP, [D-Arg¹, D-Pro², D-Trp^7,9, Leu¹¹]-SP and [D-Pro², D-Trp^7,9]-SP by CD, NMR and MD simulationsPRABHU, Arati; MALDE, Alpeshkumar; COUTINHO, Evans et al.Peptides (New York, NY. 1980). 2005, Vol 26, Num 5, pp 875-885, issn 0196-9781, 11 p.Article

Cellules de Langerhans et substance P = Langerhans cells and substance pHAMZEH, H; MISERY, L.Les Nouvelles dermatologiques. 2001, Vol 20, Num 8, pp 529-533, issn 0752-5370, 1Article

Substance P immunoreactivity in rosaceaKÜRKCÜOGLU, N; ALAYBEYI, F.Journal of the American Academy of Dermatology. 1991, Vol 25, Num 4, pp 725-726, issn 0190-9622Article

The possible role of substance P in the allergic reaction, based on two different provocation modelsNIEBER, K; BAUMGARTEN, C; WITZEL, A et al.International archives of allergy and applied immunology. 1991, Vol 94, Num 1-4, pp 334-338, issn 0020-5915Conference Paper

Behavioural characterization of substance P-induced nociceptive response in miceTAKAHASI, K; SAKURADA, T; SAKURADA, S et al.Neuropharmacology. 1987, Vol 26, Num 9, pp 1289-1293, issn 0028-3908Article

Role of Substance P in Renal Injury During DOCA-Salt HypertensionYOUPING WANG; WANG, Donna H.Endocrinology (Philadelphia). 2012, Vol 153, Num 12, pp 5972-5979, issn 0013-7227, 8 p.Article

Neuroimmunomodulation : classical and non-classical cellular activationAGRO, A; STANISZ, A. M.Advances in neuroimmunology. 1995, Vol 5, Num 3, pp 311-319, issn 0960-5428Article

Peptidergic innervation of the pars distalis of the adenohypophysisGONG JU; SHAO-JUN LIU; XU ZHANG et al.Neuroendocrinology (Basel). 1991, Vol 53, pp 41-44, issn 0028-3835, 4 p., SUP1Conference Paper

Substance P-like immunoreactivity in human prenatal hippocampal formationDEL FIACCO, M; DIANA, A; FLORIS, A et al.International journal of developmental neuroscience. 1990, Vol 8, Num 3, pp 289-297, issn 0736-5748, 7 p.Article

Time course of the alteration in dorsal horn substance P levels following formalin : blockade by naloxoneMCCARSON, K. E; GOLDSTEIN, B. D.Pain (Amsterdam). 1990, Vol 41, Num 1, pp 95-100, issn 0304-3959Article

Tools for tachykinin and neuropeptide research: a conference reportBURCHER, E; CHAHL, L. A.Neuroscience letters. 1988, Vol 86, Num 1, pp 38-44, issn 0304-3940Article